Sage Journals: Discover world-class research

Abstract

Background

In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment.

Purpose

This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends.

Methodology

A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis.

Results

The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration.

Conclusion

The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.

Keywords

Nutraceuticals antioxidant hepatoprotective antimycobacterial biomimetic synthesis

Introduction

Phytochemicals derived from diverse plants and crude plant extracts have found applications in both contemporary and traditional medical practices. These bioactive compounds serve as medications and nutraceuticals, playing a crucial role in the treatment and management of various chronic conditions. From addressing obesity and cardiovascular diseases (CVDs) to tackling diabetes, infectious diseases, neoplasms, neurological disorders, and inflammatory diseases, these botanical derivatives contribute to the expansive landscape of therapeutic interventions.^1–4 In contemporary contexts, the term “polyphenol” encompasses a broad category, encompassing chemically altered or polymerized derivatives such as tannins, chalcones, phenolic acids, and flavonoids. Recent research strongly supports the role of polyphenols in safeguarding against degenerative illnesses, including CVD, cancer, and neurological disorders.^{5, 6} These compounds serve as potent antioxidants, reinforcing the functions of antioxidant vitamins and enzymes, and acting as a front-line defense against oxidative stress induced by an excess of Reactive Oxygen Species (ROS). While much of the evidence supporting their antioxidant activity is derived from in vitro studies, a growing body of data suggests that in vivo, polyphenols may exert effects beyond their role as antioxidants. Their capacity to influence cell signaling pathways emerges as a key factor in elucidating the mechanisms underlying the impacts of dietary regimens rich in polyphenols.^{7, 8}

Tannins, polyphenolic compounds with molecular weights ranging from 500 to 20,000 Da, are widely distributed across various plant species, residing in stalks, fruits, leaves, roots, and peels.⁹ The concentration and specific types of tannins are regulated by the respective plant species. Within the realm of plant physiology, tannins are categorized as secondary metabolites and can be classified into four groups: ellagitannins (ETs), gallotannins, hydrolyzable tannins, and condensed tannins.^{10, 11}

ETs represent quinic acid or glucose esters of ellagic acid (EA), originating from the oxidative interaction of hexahydroxydyphenic acid (HHDP)-derived gallotannins with at least two galoyl units. Upon hydrolysis, this group is released and subsequently undergoes either spontaneous lactonization or rearrangement to form EA. The catalog of ET structures is extensive, with claims of more than 500 distinct structures.¹² Oaks’ bark, primarily sourced from Quercus spp., stands out as the main reservoir of ETs. As outlined by Bianco et al., the classification of ETs into polymeric, oligomeric, or monomeric forms (degree of polymerization) is contingent upon the quantity of HHDP groups present in the molecule.¹³

Chalcones, a significant dietary polyphenol, belong to the class of polyphenolic substances derived from flavonoids in plants. As a primary family of natural compounds, chalcones exhibit widespread distribution in tea, vegetables, soy-based foods, fruits, and spices and are considered predecessors of isoflavonoids and flavonoids. The term “chalcone” finds its origin in the Greek word “chalcos,” meaning bronze. Natural chalcones, present in flower petals and various plant parts such as roots, botanicals, heartwood, bark, leaves, and fruits, as well as their synthetic counterparts, showcase diverse biological activities.¹⁴ This versatility has garnered continuous attention from both the business and academic realms. Structurally, chalcones, also known as 1,3-diaryl-2-propen-1-ones, feature two aromatic rings connected by a three-carbon-unsaturated carbonyl system, representing a type of open-chain flavonoid (Figure 1a).

Figure 1.

(a) Chalcone and (b) Ellagic Acid.

Several pure chalcones have successfully transitioned into clinical trials or human experiments. Licochalcones, derived from the licorice plant, exhibits a spectrum of biological actions, including anti-malarial, anti-inflammatory, chemopreventive, anti-fungal, anti-bacterial, anti-spasmodic, anti-tumor, and anti-oxidant effects.^{15, 16} Both chalcones and dihydrochalcones are abundant in nutritional sources found in acidic and apple fruits. Interestingly, these compounds may contribute more substantially to the daily intake of unprocessed or organic polyphenolic components when compared to other extensively studied flavonoids.¹⁷ Chalcone glucoside, a primary pigment responsible for the yellow hue in flowers, is a noteworthy compound.

This study is designed to deepen our understanding of EA’s potential as a future therapeutic agent. The emphasis will be on elucidating its natural sources, and synthesis, accompanied by a comprehensive summary of its most significant pharmacological properties. Through this exploration, we aim to uncover the potential avenues for harnessing EA in future therapeutic interventions.

EA

EA belongs to the polyphenol extractives, specifically the tannins, and is widely distributed in dicotyledons.¹⁸ Structurally, EA is a derivative of chromene-dione (2,3,7,8-tetrahydroxy-chromeno[5,4,3-cde] chromene-5,10-dione; C₁₄H₆O₈; molecular weight: 302.194 g/mol), featuring a hydrophilic moiety with four hydroxyl groups and a lipophilic moiety with two hydrocarbon rings.¹⁹ This unique structure imparts to EA the capacity to participate in antioxidant redox processes and accept electrons from various substrates.^{20, 21} The chemical structure of EA is shown in Figure 1b.²²

Synthesis of EA

EA synthesis is achievable through a variety of methods, such as oxidative coupling reactions, Ullmann coupling, and lactonization (Figure 2). The synthesis of EA and its 4,4’-di-O-alkyl derivatives from gallic acid was detailed by Alam et al.²³ The process involved an oxidative reaction between gallic acid and o-chloranil, resulting in the synthesis of EA through Ullmann coupling. The functionalized methyl bormogallate was transformed into a biphenyl, which underwent lactonization to yield EA and its alkoxy derivatives.²³

Figure 2.

Oxidative Coupling of Gallic Acid to Yield Ellagic Acid.

Yu et al.²⁴ utilized glucansucrase derived from Leuconostoc mesenteroides B-512 FMCM and sucrose for the transglucosylation of EA glucoside (Figure 3). The enzymatically produced product underwent purification through C₁₈ column chromatography and a 50% ethyl acetate fraction. Employing response surface methods with 150 mM sucrose, 300 mU/mL glucansucrase, and 5 mM EA, the yield of EA glucoside reached 69% (3.47 mM). Remarkably, synthetic EA glucoside exhibited superior water solubility, increased protection of brain nerve cells (SH-SY5Y) by up to 58%, a threefold reduction in cortisol, and a fourfold inhibition of acetylcholinesterase (AChE) compared to EA. These results suggest the potential employment of the neuroprotective drug EA glucoside.²⁴

Figure 3.

Optimization of Ellagic Acid Glucoside.

In a study by Alam et al., EA synthesis was accomplished with a 48% yield over four steps, starting from methyl gallate.²⁵ However, there was an expectation of achieving a more concise and efficient synthesis. Methyl gallate, obtainable commercially or through the methylation of gallic acid, was subjected to various oxidants, including cerium ammonium nitrate, phenyliodine diacetate (PIDA), ferric chloride hexahydrate, and ferric chloride silica. The treatment with PIDA (1.5 equivalent) in boron trifluoride etherate (1.5 mL) at room temperature proved to be the most successful dimerization protocol, yielding the dimeric precursor in 80% after 16 hours. The biaryl was then quantitatively converted to the natural product when heated at reflux in aqueous methanol (1:1) for 24 hours. Remarkably, allowing the phenyliodine bis (trifluoroacetate) reaction mixture to stir at room temperature for 24 hours led to complete cyclization, providing the natural product in 83% yield directly from methyl gallate (Scheme 3; Figure 4). This approach represents an improvement in the synthesis of the bioactive natural product EA.²⁵

Figure 4.

Note: BeF₃ OEt₂: Boron trifluoride etherate; FeCl₃·6H₂O: Ferric chloride hexahydrate; FeCl₃·SiO₂: Ferric chloride silica; MeOH: Methanol; PIFA: Phenyliodine bis (trifluoroacetate).

Sources and Pharmacological Effects

EA, a naturally occurring phenol antioxidant that is present in vegetables and fruits, has a high correlation with a lower chance of contracting chronic illnesses, including CVD and cancer. EA is found in a variety of vegetables and fruits, including persimmons, raspberries, pomegranates, black plums, peaches, and wild strawberries (Table 1).²⁶ It may exist as derivatives or in free form, mostly as complex polymers referred to as ETs, which can be degraded by gut flora and physiological pH, levels of plasma boost of the acid following the consumption of vegetables as well as fruits.²⁷ A thorough and current assessment of the biological activities of EA and prospective therapeutic uses was the goal of the Shakeri et al.’s study. EA is found in nuts and fruits in two different forms: bound (ETs) and coupled with hexahydroxydiphenic acid. Many biological characteristics, including antidiabetic, apoptosis-inducing effects, anticancer, and antioxidant, are shown by EA. These pharmacological and biological characteristics are important for treating a number of human disorders. EA is a potential therapeutic agent against human illnesses, including cancer, due to its numerous modes of action.²⁸

Table 1.

Different Sources of Ellagic Acid.

Source	Name	Parts	References
Blackberry	Rubus ursinus	Fruit	Daniel et al.²⁹
Pyrenean oak	Quercus pyrenaica	Wood	Alañón et al.³⁰
Red raspberry	Rubus idaeus	Fruit	Määttä-Riihinen et al.³¹
Strawberry	Fragaria ananassa	Fruit	Määttä-Riihinen et al.³¹
Kakadu plum	Terminalia ferdinandiana	Fruit	Konczak et al.³²
Eucalyptus	Eucalyptus globulus	Leaves	Liu et al.³³
Walnuts	Juglans nigra	Seed and nuts	Daniel et al.²⁹

Biological Activity of EA

EA is still being used as a test substance, and the findings are optimistic. Still, ETs and EA derivatives have also been extensively studied, and it appears that they have more potential to develop. Infectious agents including viruses, fungi, bacteria, and even protozoa have been the subject of reports of their action on diseases.^34–37 Furthermore, the GABAergic system involvement of EA/ETs, inhibition of important enzymes like AChE, protein tyrosine phosphatases, and aldose reductase, interaction with serotonergic as well as adrenergic systems and suppression of proinflammatory markers, provide a strong foundation for potential breakthroughs in the treatment and/or prevention of many illnesses and associated clinical complications.^{38, 39} For instance, some recent research indicated that EA may function as an AChE inhibitor, raising levels of acetylcholine in the brain. As a consequence, cognitive dysfunctions in neurodegenerative diseases like Alzheimer’s disease may be partially reduced or even reversed.^{40, 41} Last, but not least, it has been revealed that one of EA’s most well-known effects, the prevention of melanogenesis, is at least largely a result of its antioxidant strength.⁴²

Some possible biological uses of EA, ETs, and derivatives are summarized in Table 2 and Figure 5. It is evident from research conducted in the last 10 years that there are several potential uses for EA and ETs in the pharmaceutical and biomedical industries.

Table 2.

Impacts of Ellagic Acid, Ellagitannins and their Derivatives.

Activity	Main Features	Active Compounds	References
Anti-mycobacterial	Slowed the Mycobacterium tuberculosis typus humanus ATCC 27294 development and the patient strain of the disease, both of which are susceptible to common antituberculosis medications.	Punicalagin	Bate-Smith⁴³
Anti-inflammatory	Potential suppression of prostaglandin E2, interleukin-6, and nitric oxide production carried on by lipopolysaccharides.	Gallic acid, ellagic acid, and punicalagin A and B	Asres et al.⁴⁴
Treatment of type 2 diabetes mellitus	Protein tyrosine phosphatase) inhibition.	Ellagitannins and ellagic acid from Agrimonia pilosa Ledeb.	BenSaad et al.⁴⁵
Anti-hyperlipidemic	Effectively eliminating induced hyperlipidemia in mice, EA-CoQ10 nanoparticles.	Ellagic acid	Nguyen et al.⁴⁶
Neuroprotective in sporadic Alzheimer’s disease	Reduced “acetylcholinesterase” activity, oxidative stress profile, amyloid-β plaque level, and pro inflammatory markers in mice induced with sporadic Alzheimer’s disease.	Ellagic acid	Ratnam et al.⁴⁷

Figure 5.

Overview of Ellagic Acid Activity.

Anti-inflammatory

EA has been discovered to form a bond with one of the precursor proteins, p50, of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), specifically p105 (Figure 6). This bonding impedes the ability of NF-κB to bind to a specific DNA domain, thereby preventing the expression of genes that are typically regulated by NF-κB.⁴⁸ EA has an additional function regarding NF-κB, which involves inhibiting the phosphorylation of inhibitor of nuclear factor kappa B. This inhibition further prevents the subsequent translocation of NF-κB into the nucleus.⁴⁹ Various pieces of evidence indicate that EA can inhibit the NF-κB pathway, leading to the downregulation of the expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), cyclooxygenase-2, and IL-6.^50–52

Figure 6.

Note: COX-2: Cyclooxygenase-2; EA: Ellagic acid; iNOS: Inducible nitric oxide synthase; IκB: Inhibitor of nuclear factor kappa B; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-α: Tumor necrosis factor alpha.

A recent study states that EA, a natural polyphenol compound known for activating sirtuin 6 (SIRT6), exhibits protective effects against cisplatin-induced nephrotoxicity. Pretreatment with EA effectively reduces the cytotoxicity of cisplatin in both primary renal cells and transformed C3H mouse kidney-1 cells. Furthermore, EA demonstrated the ability to improve renal function and alleviate apoptosis and fibrosis induced by cisplatin in mice. Additionally, EA reduced the expression of nephrotoxicity-associated inflammatory factors, IL-1β and IL-6, both in vitro as well as in vivo. In terms of mechanisms, EA reversed the reduction in SIRT6 expression caused by cisplatin and mitigated the increased expression of TNF-α induced by cisplatin. The findings offer a preclinical foundation for considering EA as a viable and promising mediator to mitigate cisplatin-induced acute kidney injury. Moreover, they support the potential role of EA as an adjunctive therapy in future cancer treatments.⁵³

Antioxidants

EA is one of the key antioxidants, along with well-known vitamins like ascorbic acid and α-tocopherol.⁵⁴ Its free radical scavenging action, which has been suggested to be equivalent to that of important vitamins, has been linked to its inherent antioxidant characteristics. EA has the capacity to scavenge a broad range of reactive nitrogen and oxygen species due to the presence of four hydroxyl and two lactone functional groups.⁵⁵ In fact, studies have demonstrated that at physiological pH, EA in an aqueous solution may inactivate peroxyl radicals, nitrogen dioxide (NO₂), and peroxynitrite, in addition to hydroxyl radicals.^{56, 57}

In decreasing order of scavenging rates, hydroxyl (OH)>methoxyl (OCH₃)>nitrogen dioxide (NO₂), Tiwari and Mishra showed that EA is an effective radical scavenger, notably against NO₂, OH, and OCH₃.⁵⁸ According to these scientists, EA should generally be a more effective scavenger of ROS than reactive nitrogen species. The metabolites of EA are also capable of effectively scavenging a variety of free radicals, sometimes even quicker than EA itself; therefore, its antiradical activity is not diminished throughout metabolism.

Cancer Prevention and Treatment

Several studies have presented evidence supporting the chemo-preventive and therapeutic properties of EA, whether obtained from the diet or administered through optimized matrices to enhance bioavailability.⁵⁹ EA’s potential lies in its ability to counteract oxidative stress-induced DNA damage, preventing mutations in proto-oncogenes and tumor suppressor genes. In a study involving Dalton’s lymphoma-bearing mice, various doses of EA (40, 60, and 80 mg/kg body weight) effectively reduced Protein C signaling, associated with cell proliferation and tumor growth, through NF-κB. Additionally, EA enhanced antioxidant defense mechanisms, providing insights into its role in cancer prevention.⁶⁰ In a recent study, Ma et al., showed that EA was first recognized as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2). Moreover, it exhibited substantial inhibitory effects on SHP2-E76K and SHP2-E76A mutants. Cell proliferation experiments further validated the capacity of EA to impede the proliferation of diverse cancer cells.⁶¹

Glucose and Lipid Lowering

Increased lipid and glucose levels, along with abdominal obesity, high blood pressure, and low high-density lipoprotein cholesterol, are factors that heighten the risks of heart disease, diabetes, and stroke, constituting the primary features of metabolic syndrome. Oxidative stress plays a role in the development of type 2 diabetes and the accompanying vascular complications.^{62, 63} EA exhibits favorable effects on glucose metabolism and diabetes in murine models, including the reduction of glucose levels, antioxidant, antiglycation, and anti-inflammatory effects, as well as the prevention of microvascular and macrovascular diabetic complications.⁶⁴ In a recent investigation, diabetic rats on a high-fat diet were administered both free EA and EA nanoparticles. The findings indicated that EA nanoparticles exhibited prolonged improvements in glucose levels and body weight compared to conventional EA.⁶⁵

Hepatoprotective

EA is credited with hepatoprotective effects due to its enhancement of hepatic functions under toxic and pathological conditions. This is attributed to its array of properties, including antioxidant, anti-hepatotoxic, anti-steatotic, anti-cholestatic, anti-fibrogenic, anti-hepatocarcinogenic, and anti-viral attributes.⁶⁶ Experiments conducted on murine models have elucidated the molecular mechanisms through which EA exerts its hepatoprotective role. These mechanisms involve scavenging free radicals, regulating antioxidant enzymes, modulating the synthesis of proinflammatory cytokines, and controlling lipid synthesis and degradation, among other factors.⁶⁶

Notably, EA demonstrates potential anti-viral properties against hepatitis B⁶⁷ and hepatitis C viruses,⁶⁸ both of which can lead to long-term complications, such as fibrosis, cirrhosis, and hepatocellular carcinoma.⁶⁹

Skin Diseases and Cosmetics

To assess the potential protective impact of EA on keratinocytes and human dermal fibroblasts, Bae et al. subjected these cells to ultraviolet-B (UV-B) radiation and administered the phenolic compound at concentrations ranging from 1 to 10 µM. The results showed a reduction in UV-B damage in both cell types, accompanied by a decrease in collagen levels due to decreased production of metalloproteinase.⁷⁰ Furthermore, the authors discovered that the topical application of EA at a concentration of 10 µM shielded hairless mice from skin wrinkle formation upon UV-B exposure. This favorable outcome was linked to a decreased production of proinflammatory cytokines (IL-1β and IL-6) and the alleviation of intercellular adhesion molecule-1 expression.⁷⁰

The incorporation of EA as a functional ingredient in cosmetic products has been suggested owing to its antioxidant, skin-lightening, and sunscreen properties. To enhance EA’s solubility and stability, attempts have been made to prepare gold nanoparticles enveloped with chitosan for EA absorption.⁷¹ Favorable and promising outcomes were achieved in the evaluation of the mentioned properties, emphasizing that the nanoparticles were produced in accordance with green chemistry principles.⁷²

Clinical Investigations

In this article, we have incorporated clinical trials specifically assessing the effectiveness of EA as outlined in Table 3.

Table 3.

Ellagic Acid in Clinical Research.

Clinical Study	Findings	References
Diabetes and insulin resistance	Promote a decrease in blood glucose levels.	Banihani et al.⁷⁹ Parsaeyan et al.⁸⁰
Performance during exercise	Enhances strength and endurance and expedites recovery post-exercise.	Ammar et al.⁸¹
Prostatic carcinoma	Adjuvant therapy in chemotherapeutic treatment: ellagic acid exhibits potential advantages, including a diminished likelihood of developing neutropenia compared to patients solely undergoing chemotherapy, a reduction in prostate-specific antigen levels, and alleviation of gastrointestinal side effects.	Falsaperla et al.⁸²
Body weight and composition	No notable impact on body weight, body mass index, waist circumference, or body fat percentage.	Gheflati et al.⁸³

Intellectual Capability

Liu et al. conducted a randomized clinical trial (RCT) to assess the efficacy of EA in enhancing cognitive performance in middle-aged men, utilizing the Wechsler Adult Intelligence Scale-Revised and Montreal Cognitive Assessment test. Over 12 weeks, patients were randomly allocated to receive a daily dose of 50 mg EA or a placebo. While the EA group exhibited statistically significant improvements in scores among overweight men, no differences were observed in patients with a normal body mass index.⁷³

Insomnia and Fatigue

In a small non-randomized controlled trial, the efficacy of Robuvit (an extract from the wood of Quercus robur L. containing ETs roburin A–E, EA, and gallic acid) in alleviating fatigue and insomnia was examined. Patients had the autonomy to select their respective groups, and the Fatigue Severity Scale gauged fatigue levels, while the Regensburg Insomnia Scale and Pittsburgh Sleep Quality Index assessed insomnia. Although there was a statistically significant improvement in scores related to fatigue and insomnia questionnaires after 8 weeks of Robuvit supplementation, the study does not provide comparisons between the intervention and control groups.⁷⁴

Male Fertility

In a 2014, Danish RCT, the impact of consuming tablets containing Punica granatum extract and standardized Alpinia galanga powder on the total number of motile spermatozoa (TMSC) and sperm morphology, defined by strict criteria, was assessed in adult men with diminished semen quality. Following 3 months of treatment, a statistically significant increase in TMSC was observed (p = .026). However, the difference in follow-up TMSC between groups did not reach statistical significance. No notable differences in sperm morphology were detected post-treatment. The study’s limited size (n = 66) might explain the absence of statistically significant differences. Larger RCTs are warranted, preferably focusing on evaluating EA in isolation without combination interventions.⁷⁵

Colorectal Cancer

Núñez-Sánchez et al. conducted a study to explore the potential impact of these metabolites on colorectal cancer patients (n = 52) following the administration of pomegranate extract (900 mg/day, 15 days). They examined the presence of these metabolites in the urine or tissue of both normal and malignant colons. EA was identified in colon tissue, present in both free form and as conjugates. Specifically, samples from colorectal cancer patients who received 291 mg/g of free EA demonstrated 649 ng/g in normal tissue and 195 ng/g in malignant tissue.⁷⁶

Ischemia

In a study, individuals with stable coronary heart disease were randomly assigned to either a pomegranate juice (PJ) group or a placebo group. Participants underwent electrocardiographic-gated myocardial perfusion single-photon emission computed tomographic technetium-99m tetrofosmin scintigraphy at rest and during stress at baseline and three months later. A statistically significant reduction (p < .05) in stress-induced ischemia was observed in the PJ group (summed difference score (SDS) −0.8 ± 2.7) compared to the placebo group (SDS 1.2 ± 3.1).⁷⁷

Multiple Sclerosis

In a triple-blind study, eligible patients were randomly assigned to two groups: one receiving EA (25 subjects) at a dose of 180 mg for 12 weeks and the control group (25 subjects) receiving a placebo before main meals. The assessment involved gathering data on general information, food consumption, physical action, the expanded disability status scale, anthropometric data, the pain rating index, a health questionnaire, and the fatigue severity scale before and after the 12 weeks. Additionally, serum levels of interferon-gamma, IL-17, IL-4, and transforming growth factor-beta, as well as nitric oxide (NO), were assessed using the enzyme-linked immunoassay method. The addition of EA resulted in a decrease in levels of IFNγ, IL-17, and NO while elevating IL-4 in the EA group. Conversely, no such alterations were noted in the placebo group.⁷⁸

Conclusion

The pharmacological properties of EA have been extensively explored in various preclinical and clinical studies, demonstrating its potential as a promising therapeutic agent for a wide range of health conditions. From its anti-inflammatory and antioxidant effects to its role in cancer prevention and treatment, glucose and lipid regulation, hepatoprotection, skin health, and cosmetic applications, EA has shown remarkable versatility in its pharmacological actions.

Clinical investigations have provided valuable insights into the efficacy of EA in addressing conditions such as intellectual capability, insomnia, fatigue, male fertility, colorectal cancer, ischemia, and multiple sclerosis. While many of these studies have shown promising results, further research is warranted to elucidate the underlying mechanisms of action, optimize dosage regimens, and assess long-term safety profiles.

Future Perspectives

Looking ahead, the exploration of EA’s pharmacological potential opens exciting avenues for future research and development. One promising direction involves investigating its synergistic effects with other natural compounds or conventional therapeutics to enhance efficacy and minimize adverse effects. The combination therapies may offer novel approaches for addressing complex diseases and improving patient outcomes.

Furthermore, the development of innovative delivery systems and formulations could enhance the bioavailability and stability of EA, overcoming the limitations associated with its poor solubility and rapid metabolism. Nanotechnology-based approaches, liposomal formulations, and targeted delivery systems represent promising strategies for maximizing the therapeutic benefits of EA in clinical settings.

In addition, the elucidation of specific molecular targets and signaling pathways modulated by EA will provide valuable insights into its mechanisms of action and help identify novel therapeutic targets for drug discovery and development. Advances in systems biology, high-throughput screening, and computational modeling hold great promise for accelerating the pace of discovery in this field.

Moreover, expanding our understanding of the pharmacokinetics and pharmacodynamics of EA across different populations and disease states will facilitate personalized approaches to treatment and optimize therapeutic outcomes. Population-based studies and clinical trials incorporating diverse patient cohorts will be essential for evaluating the efficacy and safety of EA in real-world settings.

The continued investigation of EA’s pharmacological effects offers tremendous potential for addressing unmet medical needs and improving public health outcomes. By leveraging interdisciplinary approaches and harnessing cutting-edge technologies, we can unlock the full therapeutic potential of EA and pave the way for the development of innovative therapies for diverse health conditions.

Abbreviations

SHP2: Src homology phosphotyrosyl phosphatase 2; EDSS: Expanded disability status scale; PRI: Pain rating index; FSS: Fatigue severity scale; IFN-γ: Interferon-gamma; IL-17: Interleukin-17; IL-4: Interleukin-4; TGF-β: Transforming growth factor-beta; NO: nitric oxide; ELISA: Enzyme-linked immunosorbent assay; SIRT6: Sirtuin 6.

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and publication of this article.

ORCID iD

Sachin Kumar

References

Aggarwal

, Kunnumakkara

, Harikumar

, . The potential of spice-derived phytochemicals for cancer prevention. Planta Med 2008; 74(13): 1560–1569. DOI: 10.1055/s-2008-1074578

Muralimanoharan

, Kunnumakkara

, Shylesh

, . Butanol fraction containing berberine or related compound from Nexrutine® inhibits NFκB signalling and induces apoptosis in prostate cancer cells. Prostate 2009; 69(5): 494–504. DOI: 10.1002/pros.20899

Roy

, Deka

, Bordoloi

, . The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett 2016; 377(1): 74–86. DOI: 10.1016/j.canlet.2016.04.017

Kaulmann

and Bohn

Carotenoids, inflammation, and oxidative stress–implications of cellular signaling pathways and relation to chronic disease prevention. Nutr Res 2014; 34(11): 907–929. DOI: 10.1016/j.nutres.2014.07.010

Goldberg

and Hasler

CM.

Functional foods–designer foods, pharmafoods, nutraceuticals. Am J Clin Nutr 1996; 64(2): 255.

Duthie

, Brown

KM.

Reducing the risk of cardiovascular disease

In: Goldberg I(ed) Functional Foods . Boston, MA: Springer, 1994, pp. 19–38. DOI: 10.1007/978-1-4615-2073-3_2

Williams

, Spencer

, Rice-Evans

Flavonoids: Antioxidants or signalling molecules?

Free Radic Biol Med 2004; 36(7): 838–849. DOI: 10.1016/j.freeradbiomed.2004.01.001

Dong

and Surh

YJ.

Dietary modulation of cell signaling pathways . London: CRC Press, 2008.

Haslam

and Cai

Plant polyphenols (vegetable tannins): Gallic acid metabolism. Nat Prod Rep 1994; 11: 41–66. DOI: 10.1039/np9941100041

10.

Khanbabaee

and Van Ree

Tannins: Classification and definition. Nat Prod Rep 2001; 18(6): 641–649. DOI: 10.1039/b101061l

11.

Ghosh

Tannins from foods to combat diseases. Int J Pharma Res Rev 2015; 4(5): 40–44.

12.

Feldman

, Sahasrabudhe

, Smith

, . Immunostimulation by plant polyphenols: A relationship between tumor necrosis factor-α production and tannin structure. Bioorgan Med Chem Lett 1999; 9(7): 985–990. DOI: 10.1016/s0960-894x (99)00110-9

13.

Bianco

, Handaji

and Savolainen

Quantitative analysis of ellagic acid in hardwood samples. Sci Total Environ 1998; 222(1-2): 123–126. DOI: 10.1016/S0048-9697(98)00294-0

14.

Di Carlo

, Mascolo

, Izzo

, . Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999; 65(4): 337–353. DOI: 10.1016/s0024-3205(99)00120-4

15.

Salehi

, Quispe

, Chamkhi

, . Pharmacological properties of chalcones: A review of preclinical including molecular mechanisms and clinical evidence. Front Pharmacol 2021;11. DOI: 10.3389/fphar.2020.592654

16.

Tsatsakis

, Docea

, Calina

, . A mechanistic and pathophysiological approach for stroke associated with drugs of abuse. J Clin Med 2019; 8(9): 1295. DOI: 10.3390/jcm8091295

17.

Tomás-Barberán

, Clifford

MN.

Flavanones, chalcones and dihydrochalcones–nature, occurrence and dietary burden. J Sci Food Agric 2000; 80(7): 1073–1080. DOI: 10.1002/(SICI)1097-0010(20000515)80:7%3C1073::AID-JSFA568%3E3.0.CO;2-B

18.

Quideau

and Feldman

KS.

Ellagitannin chemistry. Chem Rev 1996; 96(1): 475–504. DOI: 10.1021/cr940716a

19.

PubChem, National Center for Biotechnology Information, U. S. National Library of Medicine. Ellagic acid. https://pubchem.ncbi.nlm.nih.gov/compound/ellagic_acid (accessed November 14, 2023).

20.

Rossi

, Erlebacher

, Zacharias

, . The crystal and molecular structure of ellagic acid dihydrate: A dietary anti-cancer agent. Carcinogenesis 1991; 12(12): 2227–2232. DOI: 10.1093/carcin/12.12.2227

21.

Clifford

, Scalbert

Ellagitannins–nature, occurrence and dietary burden. J Sci Food Agric 2000; 80(7): 1118–1125. DOI: 10.1002/(SICI)1097-0010(20000515)80:7%3C1118::AID-JSFA570%3E3.0.CO;2-9

22.

Ríos

, Giner

, Marín

, . A pharmacological update of ellagic acid. Planta Med 2018; 84(15): 1068–1093. DOI: 10.1055/a-0633-9492

23.

Alam

, Takaguchi

and Tsuboi

Synthesis of ellagic acid and its 4, 4’-di-Ο-alky derivatives from gallic acid. J Faculty Environ Sci Technol 2005; 10(1): 111–117. DOI: 10.18926/FEST/11508

24.

, Jeong

, Yang

, . Synthesis of ellagic acid glucoside using glucansucrase from leuconostoc and characterization of this glucoside as a functional neuroprotective agent. AMB Express 2021; 11(1): 1. DOI: 10.1186/s13568-021-01265-x

25.

Daley

, and Downer-Riley

The biomimetic synthesis of balsaminone A and ellagic acid via oxidative dimerization. Beilstein Jo Organ Chem 2020; 16: 2026–2031. DOI: 10.3762/bjoc.16.169.

26.

Derosa

Maffioli P and Sahebkar A. Ellagic acid and its role in chronic diseases. Anti Inflamm Nutraceutic Chron Dis 2016; 928: 473–479. DOI: 10.1007/978-3-319-41334-1_20

27.

Landete

JM.

Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health. Food Res Int 2011; 44(5): 1150–1160. DOI: 10.1016/j.foodres.2011.04.027.

28.

Shakeri

, Zirak

, and Sahebkar

Ellagic acid: A logical lead for drug development?

Curr Pharm Des 2018; 24(2): 106–122. DOI: 10.2174/1381612823666171115094557

29.

Daniel

, Krupnick

, Heur

, . Extraction, stability, and quantitation of ellagic acid in various fruits and nuts. J Food Comp Anal 1989;2(4): 338–49. DOI: 10.1016/0889-1575(89)90005-7

30.

Alañón

, Castro-Vázquez

, Díaz-Maroto

, . Antioxidant capacity and phenolic composition of different woods used in cooperage. Food Chem 2011; 129(4): 1584–1590. DOI: 10.1016/j.foodchem.2011.06.013

31.

Määttä-Riihinen

, Kamal-Eldin

and Törrönen

AR.

Identification and quantification of phenolic compounds in berries of Fragaria and Rubus species (family Rosaceae). J Agric Food Chem 2004; 52(20): 6178–6187. DOI: 10.1021/jf049450r

32.

Konczak

, Maillot

and Dalar

Phytochemical divergence in 45 accessions of Terminalia ferdinandiana (Kakadu plum). Food Chem 2014; 151: 248–256. DOI: 10.1016/j.foodchem.2013.11.049.

33.

Liu

, Chen

, Han

, . Microwave-assisted method for simultaneous hydrolysis and extraction in obtaining ellagic acid, gallic acid and essential oil from Eucalyptus globulus leaves using Brönsted acidic ionic liquid [HO₃S (CH₂) 4mim] HSO₄. Ind Crops Prod 2016; 81: 152–161. DOI: 10.1016/j.indcrop.2015.11.074.

34.

Ratnam

, Ankola

, Bhardwaj

, . Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Rel 2006; 113(3): 189–207. DOI: 10.1016/j.jconrel.2006.04.015

35.

Vijaya Padma

, Kalai Selvi

and Sravani

Protective effect of ellagic acid against TCDD-induced renal oxidative stress: Modulation of CYP1A1 activity and antioxidant defense mechanisms. Mol Biol Rep 2014; 41: 4223–4232. DOI: 10.1007/s11033-014-3292-5

36.

Abuelsaad

, Mohamed

, Allam

, . Antimicrobial and immunomodulating activities of hesperidin and ellagic acid against diarrheic Aeromonas hydrophila in a murine model. Life Sci 2013; 93(20): 714–722. DOI: 10.1016/j.lfs.2013.09.019

37.

Bag

, Bhattacharyya

, and Chattopadhyay

RR.

The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac J Trop Biomed 2013; 3(3): 244–252. DOI: 10.1016/S2221-1691(13)60059-3

38.

Variya

, Bakrania

, Patel

SS.

Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. Pharmacol Res 2016; 111: 180–200. DOI: 10.1016/j.phrs.2016.06.013

39.

Aguilar-Zárate

, Wong-Paz

, Buenrostro-Figueroa

, . Ellagitannins: Bioavailability, purification and biotechnological degradation. Mini Rev Med Chem 2018; 18(15): 1244–1252. DOI: 10.2174/1389557517666170208144742

40.

Wink

Modes of action of herbal medicines and plant secondary metabolites. Medicines (Basel) 2015; 2(3): 251–286. DOI: 10.3390/medicines2030251

41.

Lee

, Johnson

, Talcott

ST.

Identification of ellagic acid conjugates and other polyphenolics in muscadine grapes by HPLC-ESI-MS. J Agric Food Chem 2005; 53(15): 6003–6010. DOI: 10.1021/jf050468r

42.

Ayoub

NA.

A trimethoxyellagic acid glucuronide from Conocarpus erectus leaves: Isolation, characterization and assay of antioxidant capacity. Pharm Biol 2010; 48(3): 328–332. DOI: 10.3109/13880200903131567

43.

Bate-Smith

EC.

Chromatography and taxonomy in the Rosaceae, with special reference to Potentilla and Prunus 1. J Linnean Soc Lond Bot 1961; 58(370): 39–54. DOI: 10.1111/j.1095-8339. 1961. tb01079.x

44.

Asres

, Bucar

, Edelsbrunner

, . Investigations on antimycobacterial activity of some Ethiopian medicinal plants. Phytother Res 2001; 15(4): 323–326. DOI: 10.1002/ptr.724

45.

BenSaad

, Kim

, Quah

, . Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complement Alternat Med 2017; 17: 1. DOI: 10.1186/s12906-017-1555-0

46.

Nguyen

, Seo

, Zhao

, . Ellagitannin and flavonoid constituents from Agrimonia pilosa Ledeb. with their protein tyrosine phosphatase and acetylcholinesterase inhibitory activities. Bioorgan Chem 2017; 72: 293–300. DOI: 10.1016/j.bioorg.2017.04.017

47.

Ratnam

, Chandraiah

, Meena

, . The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats. J Nanosci Nanotechnol 2009; 9(11): 6741–6746. DOI: 10.1166/jnn.2009.1461

48.

Khan

, Ansari

, and Khan

MS.

Dietary phytochemicals as potent chemotherapeutic agents against breast cancer: Inhibition of NF-κB pathway via molecular interactions in rel homology domain of its precursor protein p105

Pharmacogn Mag 2013; 9(35): 282. DOI: 10.4103/0973-1296.108140

49.

Zamani-Garmsiri

, Emamgholipour

, Rahmani Fard

, . Polyphenols: Potential anti-inflammatory agents for treatment of metabolic disorders. Phytother Res 2022; 36(1): 415–432. DOI: 10.1002/ptr.7329

50.

Rosillo

, Sanchez-Hidalgo

, Cárdeno

, . Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn’s disease. Biochem Pharmacol 2011; 82(7): 737–745. DOI: 10.1016/j.bcp.2011.06.043

51.

Mohammadinejad

, Mohajeri

, Aleyaghoob

, . Ellagic acid as a potent anticancer drug: A comprehensive review on in vitro, in vivo, in silico, and drug delivery studies. Biotechnol Appl Biochem 2022; 69(6): 2323–2356. DOI: 10.1002/bab.2288

52.

Hofseth

, Hussain

, Wogan

, and Harris

CC.

Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003; 34(8): 955–968. DOI: 10.1016/s0891-5849(02)01363-1

53.

Gao

, Peng

, Wang

, . Ellagic acid ameliorates cisplatin-induced acute kidney injury by regulating inflammation and SIRT6/TNF-α signaling. Food Sci Hum Wellness 2023; 12(6): 2232–2241. DOI: 10.1016/j.fshw.2023.03.043

54.

Jha

, Panchal

, Shah

Ellagic acid: Insights into its neuroprotective and cognitive enhancement effects in sporadic Alzheimer’s disease. Pharmacol Biochem Behav 2018; 175: 33–46. DOI: 10.1016/j.pbb.2018.08.007

55.

Salem

, Mohammaden

, Ali

, . Ellagic and ferulic acids alleviate gamma radiation and aluminium chloride-induced oxidative damage. Life Sci 2016; 160: 2–11. DOI: 10.1016/j.lfs.2016.07.006

56.

Priyadarsini

, Khopde

, Kumar

, . Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 2002; 50(7): 2200–2206. DOI: 10.1021/jf011275g

57.

Galano

, Francisco Marquez

and Pérez-González

Ellagic acid: An unusually versatile protector against oxidative stress. Chem Res Toxicol 2014; 27(5): 904–918. DOI: 10.1021/tx500065y

58.

Tiwari

, Mishra

PC.

Modeling the scavenging activity of ellagic acid and its methyl derivatives towards hydroxyl, methoxy, and nitrogen dioxide radicals. J Mol Model 2013; 19: 5445–5456. DOI: 10.1007/s00894-013-2023-5

59.

Ceci

, Lacal

, Tentori

, . Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. Nutrients 2018; 10(11): 1756. DOI: 10.3390/nu10111756

60.

Baradaran Rahimi

, Ghadiri

, Ramezani

, . Antiinflammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studies. Phytother Res 2020; 34(4): 685–720. DOI: 10.1002/ptr.6565A

61.

, Zhao

, Zhang

, . Discovery of ellagic acid as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) for cancer treatment: in vitro and in silico study. Int J Biol Macromol 2024; 254(Pt 2): 127845. DOI: 10.1016/j.ijbiomac.2023.127845

62.

Maritim

, Sanders

, and Watkins

3rd. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003; 17(1): 24–38. DOI: 10.1002/jbt.10058C

63.

Yuan

, Yang

, Chen

, . New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 2019; 20: 247–260. DOI: 10.1016/j.redox.2018.09.025

64.

Amor

, Gómez-Guerrero

, Ortega

, . Ellagic acid as a tool to limit the diabetes burden: Updated evidence. Antioxidants (Basel) 2020; 9(12): 1226. DOI: 10.3390/antiox9121226

65.

Harakeh

, Almuhayawi

, Jaouni

, . Antidiabetic effects of novel ellagic acid nanoformulation: Insulin-secreting and anti-apoptosis effects. Saudi J Biol Sci 2020; 27(12): 3474–3480. DOI: 10.1016/j.sjbs.2020.09.060

66.

García-Niño

, and Zazueta

Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacol Res 2015; 97: 84–103. DOI: 10.1016/j.phrs.2015.04.008

67.

Pathak

, Baunthiyal

, Taj

, . Virtual screening of natural inhibitors to the predicted HBx protein structure of Hepatitis B Virus using molecular docking for identification of potential lead molecules for liver cancer. Bioinformation 2014; 10(7): 428–435. DOI: 10.6026/97320630010428

68.

Reddy

, Mullick

, Kumar

, . Small molecule inhibitors of HCV replication from pomegranate. Sci Rep 2014; 4: 5411. DOI: 10.1038/srep05411

69.

Arzumanyan

, Reis

, Feitelson

MA.

Pathogenic mechanisms in HBV– and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13(2): 123–135. DOI: 10.1038/nrc3449

70.

Bae

, Choi

, Kang

, . Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Exp Dermatol 2010; 19(8): e182–e190. DOI: 10.1111/j.1600-0625.2009.01044.x

71.

Gubitosa

, Rizzi

, Fini

, . Multifunctional green synthetized gold nanoparticles/chitosan/ellagic acid self-assembly: Antioxidant, sun filter and tyrosinase-inhibitor properties. Mater Biol Appli 2020; 106: 110170. DOI: 10.1016/j.msec.2019.110170

72.

Sharifi-Rad

, Quispe

, Castillo

CMS

, . Ellagic acid: A review on its natural sources, chemical stability, and therapeutic potential. Oxid Med Cell Longev 2022; 2022: 3848084. DOI: 10.1155/2022/3848084

73.

Liu

, Yu

, Wang

, . Chronic administration of ellagic acid improved the cognition in middle-aged overweight men. Appl Physiol Nutr Metab 2018; 43(3): 266–273. DOI: 10.1139/apnm-2017-0583

74.

Belcaro

, Saggino

, Cornelli

, . Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit®. J Neurosurg Sci 2018; 62(4): 423–427. DOI: 10.23736/S0390-5616.18.04384-9

75.

Fedder

, Jakobsen

, Giversen

, . An extract of pomegranate fruit and galangal rhizome increases the numbers of motile sperm: A prospective, randomised, controlled, double-blinded trial. PLoS One 2014; 9(9): e108532. DOI: 10.1371/journal.pone.0108532

76.

Nuñez-Sánchez

, García-Villalba

, Monedero-Saiz

, . Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res 2014; 58(6): 1199–1211. DOI: 10.1002/mnfr.201300931

77.

Sumner

, Elliott-Eller

, Weidner

, . Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am J Cardiol 2005; 96(6): 810–814. DOI: 10.1016/j.amjcard.2005.05.026

78.

Jafari Karegar

, Aryaeian

, Hajiluian

, . Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: A multicentral-triple blind randomized clinical trial. Front Nutr 2023; 10: 1238846. DOI: 10.3389/fnut.2023.1238846

79.

Banihani

, Makahleh

, El-Akawi

, . Fresh pomegranate juice ameliorates insulin resistance, enhances β-cell function, and decreases fasting serum glucose in type 2 diabetic patients. Nutr Res 2014; 34(10): 862–867. DOI: 10.1016/j.nutres.2014.08.003

80.

Parsaeyan

, Mozaffari-Khosravi

and Mozayan

MR.

Effect of pomegranate juice on paraoxonase enzyme activity in patients with type 2 diabetes. J Diabetes Metab Disord 2012; 11(1): 11. DOI: 10.1186/2251-6581-11-11

81.

Ammar

, Bailey

, Chtourou

, . Effects of pomegranate supplementation on exercise performance and post-exercise recovery in healthy adults: A systematic review. Br J Nutr 2018; 120(11): 1201–1216. DOI: 10.1017/S0007114518002696

82.

Falsaperla

, Morgia

, Tartarone

, . Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 2005; 47(4): 449–455. DOI: 10.1016/j.eururo.2004.12.001

83.

Gheflati

, Mohammadi

, Ramezani-Jolfaie

, . Does pomegranate consumption affect weight and body composition? A systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res 2019; 33(5): 1277–1288. DOI: 10.1002/ptr.6322

A Review on Pharmacological Advancement of Ellagic Acid

Abstract

Background

Purpose

Methodology

Results

Conclusion

Keywords

Introduction

(a) Chalcone and (b) Ellagic Acid.

EA

Synthesis of EA

Oxidative Coupling of Gallic Acid to Yield Ellagic Acid.

Optimization of Ellagic Acid Glucoside.

Sources and Pharmacological Effects

Different Sources of Ellagic Acid.

Biological Activity of EA

Impacts of Ellagic Acid, Ellagitannins and their Derivatives.

Overview of Ellagic Acid Activity.

Anti-inflammatory

Antioxidants

Cancer Prevention and Treatment

Glucose and Lipid Lowering

Hepatoprotective

Skin Diseases and Cosmetics

Clinical Investigations

Ellagic Acid in Clinical Research.

Intellectual Capability

Insomnia and Fatigue

Male Fertility

Colorectal Cancer

Ischemia

Multiple Sclerosis

Conclusion

Future Perspectives

Abbreviations

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iD

References